Company: RVRC
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-013823
Chunk: 126

Company: Revium Rx.
Filing Date: 2025-02-14
Form: S-1
Chunk 126
---
 legally available funds for the payment thereof, and rights to receive a distribution of assets upon liquidation.

Shares History

| a. | During                                                                                         
 2022 the Company signed an investment agreement with certain investors for gross proceeds      
 of $800, according to which the Company received net amount of $800 and issued 12,904 Ordinary 
 shares NIS 0.1 par value.                                                                      |

| b. | During                                                                                    
 2023 the Company signed an investment agreement with certain investors for gross proceeds 
 of $1,594, according to which the Company received net amount of $1,594 and issued 16,244 
 Ordinary shares NIS 0.1 par value.                                                        |

Successor:

On July 23, 2024, the Company issued to the former Predecessor shareholders an aggregate of 23,171,642 restricted shares of the Company’s common stock, representing 40% of the outstanding shares of the Company immediately following closing. As of September 30, 2024, due to technical reasons, the shares haven’t been issued by the transfer agent yet. During the fourth quarter of 2024 these shares were issued. (see note 4)

Predecessor

Share-based payment

On August 10, 2023, the Predecessor adopted the 2023 Share Award Plan to directors, employees and service providers to purchase an aggregate of 23,000 shares of Ordinary shares exercisable through the tenth anniversary (10th) of date of the issuance.

On November 15, 2023, the Predecessor granted 5,657 options to purchase Company's 5,657 Ordinary Shares to Company's Chief Technology Officer. 1,415 options vested on date of grant, 1,414 options will vest on April 10, 2024, 1,414 options will vest on October 10, 2024, and 1,414 options on April 10, 2025. The exercise price is $100 per share, and the options expire on November 15, 2033.

<div align='center'>F-19</div>

REVIUM RX.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

U.S. dollars in thousands, except share and per share data

NOTE 9 – SHAREHOLDERS’ EQUITY (Cont.)

The aggregate grant date fair value of such options was $531. The fair value of the Company’s share options